Physician profile
Harold Reeves
NPI 1508890294
$22,525.11
in general payments reported to CMS, 2019-2025
74 companies · $5,125 in 2025
The $5,125 reported for 2025 was more than what 85% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,430 · 2020: $1,740 · 2021: $2,758 · 2022: $3,452 · 2023: $3,636 · 2024: $4,384 · 2025: $5,125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $11.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,133.06 |
| Education | $11.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,503.55 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $1,368.46 | 2019-2025 | |
| Ucb, INC. | $985.36 | 2019-2025 | Fintepla, Rystiggo, Briviact |
| Acadia Pharmaceuticals INC | $983.41 | 2019-2025 | Nuplazid, Daybue |
| Pfizer INC. | $869.62 | 2019-2025 | |
| Emd Serono, INC. | $832.08 | 2019-2025 | Mavenclad |
| Neurocrine Biosciences, INC. | $754.49 | 2021-2025 | Ingrezza, Ongentys |
| Biogen, INC. | $734.76 | 2019-2025 | Vumerity, Tysabri |
| Lilly USA, LLC | $730.63 | 2019-2025 | Amyvid, Kisunla, Emgality |
| Alexion Pharmaceuticals, INC. | $605.45 | 2019-2025 | Ultomiris, Soliris |
| Argenx US, INC. | $602.10 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Celgene Corporation | $595.49 | 2021-2025 | Zeposia |
| Teva Pharmaceuticals USA, INC. | $571.65 | 2019-2025 | Austedo Xr, Austedo, Austedo Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $571.06 | 2023-2025 | Hyqvia, Gammagard |
| Genzyme Corporation | $546.75 | 2019-2025 |
Show all 74 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harold Reeves listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.